To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550
A Phase 1 Study Exploring the Safety, Tolerability, and Pharmacokinetics of INCB086550 in Japanese Participants With Advanced Solid Tumors
Sponsor: Incyte Biosciences Japan GK
Terminated
The study was terminated early due to a business decision.
A PHASE1 clinical study on Solid Tumors, this trial is terminated or withdrawn. The trial is conducted by Incyte Biosciences Japan GK and has accumulated 9 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Oct 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2022 — Jul 2024 [monthly]
Terminated PHASE1
-
Sep 2022 — Dec 2022 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
▶ Show 4 earlier versions
-
Dec 2021 — Sep 2022 [monthly]
Recruiting PHASE1
-
Mar 2021 — Dec 2021 [monthly]
Recruiting PHASE1
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Biosciences Japan GK
For direct contact, visit the study record on ClinicalTrials.gov .